CD5 CAR T cell therapy (iCell Gene Therapeutics)

N/A

Report date: 2024/11/23 20:00:08

Base Information

Drug NameCD5 CAR T cell therapy (iCell Gene Therapeutics)
Drug Alias Nameanti-CD5 CAR T cells (iCell Gene)CD5CAR-T (iCell Gene Therapeutics)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionT-cell surface glycoprotein CD5 inhibitors
TargetsT-cell surface glycoprotein CD5
Therapy Area/IndicationsLymphoma, T-CellPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesIcell Gene Therapeutics (Int'L) Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesiCell Gene Therapeutics LLCiCar Bio Therapeutics Ltd
Active IndicationsN/A
Inactive IndicationsLymphoma, T-CellPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma

Other Information

ATC CodeN/A
Related LinksN/A